Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James E Balow

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Spectrum of renal diseases associated with extreme forms of insulin resistanceCarla Musso, Edward Javor, Elaine Cochran, et al.
Journal of the American Society of Nephrology : JASN|March 20, 2009
Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathyHoward A Austin, Gabor G Illei, Michelle J Braun, et al.
Kidney International Reports|December 13, 2016
Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and RituximabMeryl Waldman, Laurence H Beck, Michelle Braun, et al.
Arthritis and Rheumatism|March 13, 2003
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritisDimitrios T Boumpas, Richard Furie, Susan Manzi, et al.
The Journal of Clinical Endocrinology and Metabolism|April 17, 2019
Effects of Metreleptin on Proteinuria in Patients With LipodystrophyHo Lim Lee, Meryl A Waldman, Sungyoung Auh, et al.
Arthritis and Rheumatism|July 13, 2004
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritisKazuki Takada, Million Arefayene, Zeruesenay Desta, et al.
Kidney International|April 21, 2023
Update on scoring and providing evidence basis for assessing pathology in lupus nephritisIngeborg M Bajema, James E Balow, Mark Haas, et al.
Arthritis and Rheumatism|January 30, 2010
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation studyGabor G Illei, Yuko Shirota, Cheryl H Yarboro, et al.
Transfusion|December 3, 2003
Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosusSusan F Leitman, John F Tisdale, Charles D Bolan, et al.
Ophthalmic Genetics|March 23, 2023
A novel variant affecting the cytoplasmic tail of the FAT1 protocadherin causing coloboma and renal failure: A case reportEmile R Vieta-Ferrer, Ehsan Ullah, Delphine Blain, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Spectrum of renal diseases associated with extreme forms of insulin resistanceCarla Musso, Edward Javor, Elaine Cochran, et al.
Journal of the American Society of Nephrology : JASN|March 20, 2009
Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathyHoward A Austin, Gabor G Illei, Michelle J Braun, et al.
Kidney International Reports|December 13, 2016
Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and RituximabMeryl Waldman, Laurence H Beck, Michelle Braun, et al.
Arthritis and Rheumatism|March 13, 2003
A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritisDimitrios T Boumpas, Richard Furie, Susan Manzi, et al.
The Journal of Clinical Endocrinology and Metabolism|April 17, 2019
Effects of Metreleptin on Proteinuria in Patients With LipodystrophyHo Lim Lee, Meryl A Waldman, Sungyoung Auh, et al.
Arthritis and Rheumatism|July 13, 2004
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritisKazuki Takada, Million Arefayene, Zeruesenay Desta, et al.
Kidney International|April 21, 2023
Update on scoring and providing evidence basis for assessing pathology in lupus nephritisIngeborg M Bajema, James E Balow, Mark Haas, et al.
Arthritis and Rheumatism|January 30, 2010
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation studyGabor G Illei, Yuko Shirota, Cheryl H Yarboro, et al.
Transfusion|December 3, 2003
Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosusSusan F Leitman, John F Tisdale, Charles D Bolan, et al.
Ophthalmic Genetics|March 23, 2023
A novel variant affecting the cytoplasmic tail of the FAT1 protocadherin causing coloboma and renal failure: A case reportEmile R Vieta-Ferrer, Ehsan Ullah, Delphine Blain, et al.
Pageof 4